Chan Soon-Shiong Institute for Medicine
Clinical research center and cancer care clinic providing immuno-oncology clinical trials, molecular diagnostics, infusion and apheresis services, and supportive clinical care. The institute operates onsite clinical trial enrollment and patient-management workflows, conducts early- and later-phase oncology and non-oncology studies, and implements policies for conflict-of-interest disclosure and independent trial oversight.
Industries
Nr. of Employees
small (1-50)
Chan Soon-Shiong Institute for Medicine
Products
Apheresis Program
Specialized apheresis procedures provided for patient treatment and clinical research.
Therapeutic Phlebotomy
Therapeutic phlebotomy services administered under clinical medical supervision.
Blood Transfusion Services
Professional blood transfusion services supporting oncology and medical patients.
Vaccine Services
Specialized vaccine services provided as part of patient care and treatment regimens.
Anktiva
Anktiva (N-803) is a proprietary IL-15 superagonist that selectively activates NK cells and T effector cells without activating regulatory T cells.
ResQ201A: Clinical Trial Of N-803 Plus Tislelizumab and Docetaxel versus Docetaxel Monotherapy in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer
A randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel versus docetaxel monotherapy in participants with advanced or metastatic non-small cell lung cancer.
Apheresis Program
Specialized apheresis procedures provided for patient treatment and clinical research.
Therapeutic Phlebotomy
Therapeutic phlebotomy services administered under clinical medical supervision.
Blood Transfusion Services
Professional blood transfusion services supporting oncology and medical patients.
Vaccine Services
Specialized vaccine services provided as part of patient care and treatment regimens.
Anktiva
Anktiva (N-803) is a proprietary IL-15 superagonist that selectively activates NK cells and T effector cells without activating regulatory T cells.
ResQ201A: Clinical Trial Of N-803 Plus Tislelizumab and Docetaxel versus Docetaxel Monotherapy in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer
A randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel versus docetaxel monotherapy in participants with advanced or metastatic non-small cell lung cancer.
Services
Patient screening, intake, eligibility review, in-person screening visits, treatment administration and follow-up for multiple oncology and selected non-oncology trials.
Collection of cellular material by apheresis and administration of infusions for investigational and standard therapies.
Pharmacy oversight for investigational products including storage, dispensing, and regulatory compliance.
Medical nutrition therapy and oncology-specific nutrition support implemented by a registered dietitian integrated with patient care.
Clinical blood transfusion services and therapeutic phlebotomy to support patient care and trial requirements.
Patient screening, intake, eligibility review, in-person screening visits, treatment administration and follow-up for multiple oncology and selected non-oncology trials.
Collection of cellular material by apheresis and administration of infusions for investigational and standard therapies.
Pharmacy oversight for investigational products including storage, dispensing, and regulatory compliance.
Medical nutrition therapy and oncology-specific nutrition support implemented by a registered dietitian integrated with patient care.
Clinical blood transfusion services and therapeutic phlebotomy to support patient care and trial requirements.
Expertise Areas
- Clinical trial management
- Immuno-oncology and cell therapy
- Molecular diagnostics for oncology
- Patient enrollment and site-based screening
Key Technologies
- Adoptive cell therapy
- NK-cell based immunotherapy
- IL-15 superagonist biologics
- Tumor Treating Fields (device-based therapy)